These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6199590)

  • 1. Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    J Cardiovasc Pharmacol; 1984; 6(1):1-6. PubMed ID: 6199590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    Eur J Clin Pharmacol; 1983; 25(6):773-7. PubMed ID: 6662176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients.
    Lévy-Prades R; Philip F; Danays T; Serradimigni A; Cano JP
    Arzneimittelforschung; 1989 Aug; 39(8):903-8. PubMed ID: 2818679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of mexiletine in renal insufficiency.
    Baudinet G; Henrard L; Quinaux N; El Allaf D; de Landsheere C; Carlier J; Dresse A
    Acta Cardiol Suppl; 1980; (25):55-65. PubMed ID: 6966453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias.
    Ohashi K; Ebihara A; Hashimoto T; Hosoda S; Kondo K; Oka T
    Arzneimittelforschung; 1984; 34(4):503-7. PubMed ID: 6540110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption, distribution and elimination of mexiletine.
    Prescott LF; Pottage A; Clements JA
    Postgrad Med J; 1977; 53 Suppl 1():50-5. PubMed ID: 876954
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
    Jounela AJ; Pentikäinen PJ; Oksanen K
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):276-82. PubMed ID: 7107076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and bioavailability of mexiletine in healthy subjects.
    Häselbarth V; Doevendans JE; Wolf M
    Clin Pharmacol Ther; 1981 Jun; 29(6):729-36. PubMed ID: 7226704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects.
    Paczkowski D; Sadowski Z; Filipek M; Koliński P
    Pol J Pharmacol Pharm; 1990; 42(4):365-75. PubMed ID: 2097598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rifampicin treatment on the kinetics of mexiletine.
    Pentikäinen PJ; Koivula IH; Hiltunen HA
    Eur J Clin Pharmacol; 1982; 23(3):261-6. PubMed ID: 6129140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antiarrhythmic activity of mexiletine and lorcainide on ventricular arrhythmias.
    Meinertz T; Kasper W; Stengel E; Waldecker B; Löllgen H; Jähnchen E; Bechtold H; Just J
    Z Kardiol; 1982 Jan; 71(1):35-8. PubMed ID: 7039160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline pharmacology, electrophysiology and pharmacokinetics of mexiletine.
    Middleton D
    Acta Cardiol Suppl; 1980; (25):45-53. PubMed ID: 6990666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mexiletine, an anti-arrhythmia agent for acute stage of myocardial infarction].
    Hayakawa H; Ino T
    Nihon Rinsho; 1983 Dec; 41(12):2748-55. PubMed ID: 6674559
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of mexiletine in renal insufficiency.
    El Allaf D; Henrard L; Crochelet L; Delapierre D; Carlier J; Dresse A
    Br J Clin Pharmacol; 1982 Sep; 14(3):431-5. PubMed ID: 7126416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.
    Wing LM; Meffin PJ; Grygiel JJ; Smith KJ; Birkett DJ
    Br J Clin Pharmacol; 1980 May; 9(5):505-9. PubMed ID: 6994791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cirrhosis of the liver markedly impairs the elimination of mexiletine.
    Pentikäinen PJ; Hietakorpi S; Halinen MO; Lampinen LM
    Eur J Clin Pharmacol; 1986; 30(1):83-8. PubMed ID: 3709636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.
    Mitchell BG; Clements JA; Pottage A; Prescott LF
    Br J Clin Pharmacol; 1983 Sep; 16(3):281-4. PubMed ID: 6626420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dissolution and oral bioavailability of mexiletine capsules modified for clinical trial. A preliminary report.
    Chan K; Tse J; Deeks PA; Pilling M
    Methods Find Exp Clin Pharmacol; 1983 Sep; 5(7):471-8. PubMed ID: 6668966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
    Woosley RL; Wang T; Stone W; Siddoway L; Thompson K; Duff HJ; Cerskus I; Roden D
    Am Heart J; 1984 May; 107(5 Pt 2):1058-65. PubMed ID: 6326558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective disposition of mexiletine in man.
    Grech-Belanger O; Turgeon J; Gilbert M
    Br J Clin Pharmacol; 1986 May; 21(5):481-7. PubMed ID: 3718807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.